dalfampridine (ampyra) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

  • Now
Dalfampridine is a potassium channel blocker, used as a research tool in characterizing subtypes of the potassium channel. Dalfampridine has also been used as a drug, to manage some of the symptoms of multiple sclerosis, and is indicated for symptomatic improvement of walking in adults with several variations of the disease. The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated. Dalfampridine is a broad spectrum potassium channel blocker. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.   NCATS

  • Mol. Mass: 94.1145
  • ALogP: 0.66
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$0.8325 - $25.0082
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

4-aminopyridine | 4-ap | 4-pyridinamine | 4-pyridylamine | ampyra | ampyra extended release | avitrol | dalfampridine | el-970 | fampridina | fampridine | fampridine-sr | fampridinum | fampyra | gamma-aminopyridine | n07xx07 | neurelan | p-aminopyridine | pyridin-4-amine


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue